- A new study found that patients on chronic hemodialysis with depression are frequently not interested in modifying or initiating anti-depressant treatment.
- Kidney specialists caring for these patients are often unwilling to modify or initiate anti-depressant therapy even when patients are willing to accept recommendations from nurses to do so.
Washington, DC (Jan. 26, 2017) -- Many patients with kidney failure who are receiving chronic hemodialysis have depressive symptoms but do not wish to receive aggressive treatment to alleviate them, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The study also found that when patients were willing to accept treatment for depression, kidney specialists commonly do not prescribe it.
Depression is common in patients receiving chronic hemodialysis but may be ineffectively treated. To investigate the acceptance of anti-depressant treatment by patients on chronic hemodialysis and their doctors, a team led by Steven Weisbord, MD, MSc and Julio Pena-Polanco, MD (VA Pittsburgh Healthcare System and University of Pittsburgh School of Medicine) asked 101 hemodialysis patients in a clinical trial to complete a monthly questionnaire asking about depressive symptoms.
Of the 101 patients who were followed for at least 1 year, 39 met criteria for depression based on their answers in the questionnaire. These 39 patients had depression on 147 of 373 (39%) monthly assessments. At 70% of these 147 assessments, patients were receiving anti-depressant therapy and in 51 of 70 (70%) assessments, patients did not accept nurses' recommendations to intensify treatment. At 44 assessments, patients with depression were not receiving anti-depressant therapy and in 40 instances (91%) did not accept recommendations to start treatment. The primary reason patients refused the recommendations was because they felt their depression was attributable to an acute event, chronic illness, or dialysis. In 11 of 18 instances (61%) in which patients accepted the recommendation, kidney specialists were unwilling to provide treatment.
"The Centers for Medicare and Medicaid Services' Quality Improvement Program for end-stage renal disease recently mandated that all dialysis facilities report individual patient screening and treatment plans for depression; however, there is a paucity of evidence documenting the effectiveness of anti-depressant treatment in this patient population and it remains unknown whether patients on dialysis want treatment for depression," said Dr. Weisbord. "Our study demonstrated that many patients on chronic hemodialysis have depressive symptoms but do not wish to receive aggressive treatment to alleviate these symptoms. We also noted that when patients are willing to accept treatment, renal providers commonly do not prescribe treatment."
In an accompanying editorial, Maree Hackett, PhD and Meg Jardine, PhD (University of Sydney, in Australia) noted that potential underlying reasons for the high rates of depression in dialysis patients include the overlap of some risk factors for depression and kidney failure, as well as changes in physiological and psychological processes as a result of living with kidney failure. "Depression in people receiving dialysis treatment is associated with lower quality of life, increased hospitalizations and, in all likelihood, shortened survival," they wrote. "The importance of the inner experience may get lost... in a setting of intensive medical intervention, intercurrent comorbidities, and high rates of unwelcome events," they added.
Study co-authors include Maria Mor, PhD, Fadi Tohme, MD, Michael Fine, MD, MSc, and Paul Palevsky, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Acceptance of Anti-Depressant Treatment by Patients on Hemodialysis and their Renal Providers," will appear online at http://cjasn.
The editorial, entitled "We Need to Talk about Depression and Dialysis: But What Questions Should We Ask and Does Anyone Know the Answers?" will appear online at http://cjasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 16,000 members representing 112 countries. For more information, please visit http://www.